Glycyl-Exatecan (TFA)

Glycyl-Exatecan TFA (Glycyl-DX-8951 TFA), a derivative of Exatecan (HY-13631), is an anticancer agent. Glycyl-Exatecan TFA has significantly antitumor activity. Glycyl-Exatecan TFA can be used for cancers like solid tumors research[1].

Product Specifications

CAS Number

[1883333-57-0]

Product Name Alternative

Glycyl-DX-8951 (TFA) ; Exatecan analog 2 (TFA)

UNSPSC

12352005

Target

Drug Derivative

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

98.37

Solubility

DMSO : 100 mg/mL

Smiles

O=C(N[C@H]1CCC2=C3C1=C(CN4C(C(COC([C@@]5(CC)O)=O)=C5C=C46)=O)C6=NC3=CC(F)=C2C)CN.O=C(O)C(F)(F)F

Molecular Formula

C28H26F4N4O7

Molecular Weight

606.52

References & Citations

[1]Wente MN, et al. DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors. Invest New Drugs. 2005 Aug;23 (4) :339-47.